Podcasts about astct

In the next installment of ASTCT's Titans of Transplant series, Dr. Shernan Holtan sits down with Dr. Daniel Weisdorf—renowned leader, mentor and pioneer in cellular therapy and transplantation—for a reflective and engaging conversation on the evolution of the field. From the early days of sibling-only donors and bone marrow harvests to today's innovations in GVHD prophylaxis and cord blood transplantation, Dr. Weisdorf shares personal anecdotes, pivotal clinical insights and lessons in mentorship, writing and research. Together, they explore the milestones, challenges and future directions in transplant and cellular therapy—offering a powerful perspective on what it means to make a lasting impact in patient care and scientific progress.

In the next episode of ASTCT's "Titans of Transplant," Dr. Shernan Holtan hosts Dr. Renier Brentjens, a pioneer in CAR T-cell therapy and a transformative leader in transplantation and cellular therapy. Dr. Brentjens discusses the challenges and breakthroughs behind developing the first chimeric antigen receptors (CARs), the pivotal discovery of CD19-targeting hybridomas, and the determination needed to turn bold ideas into clinical reality. Tune in for an insightful look at how early experiments paved the way for today's CAR T-cell advancements, capturing the passion, persistence, and pivotal moments that shaped a new era in cancer treatment.

This episode of ASTCT Talks dives into outpatient CAR T therapy, exploring logistics, challenges, and success strategies. Host Dr. Zahra Mahmoudjafari leads a panel of experts to share insights from their innovative programs. The panel features Robb Richards, Administrative Director of Cell Therapy and Transplant at Penn Medicine; Dr. Katie Gatwood, Clinical Pharmacy Specialist at Vanderbilt University Medical Center; and Dr. Taha Al-Juhaishi, Associate Director at the University of Oklahoma's Transplant and Cell Therapy Program. Topics include outpatient program structures, toxicity management, and the evolving role of cell therapies beyond hematologic malignancies. About the Host:Dr. Zahra Mahmoudjafari is a board-certified oncology pharmacist and Clinical Pharmacy Manager in Hematologic Malignancies at the University of Kansas Cancer Center. She earned her PharmD and MBA from UMKC and focuses on clinical and operational management of cell and gene therapies. Dr. Mahmoudjafari is active in HOPA, ATOPP, and ASTCT and was honored with ASTCT's Pharmacy SIG Lifetime Achievement Award and ASCO's 40 Under 40 in Cancer Award. Meet the Panel: Robb Richards has over 20 years of oncology experience, with roles spanning private practice, IT, and leadership in healthcare systems. At Penn Medicine, he oversees CAR T therapy operations, expanding services into community hospitals. He holds degrees from Drexel University and St. Joseph's University. Dr. Katie Gatwood is a Board-Certified Oncology Pharmacist at Vanderbilt University Medical Center, where she leads the PGY2 Oncology Residency Program and chairs the ASTCT Pharmacy SIG. Her expertise spans CAR T therapy, transplant conditioning, and GVHD therapies. Dr. Gatwood is an award-winning practitioner and has authored several publications on oncology pharmacy practice. Dr. Taha Al-Juhaishi is an attending physician and clinical investigator at OU Stephenson Cancer Center, Oklahoma's only NCI-designated center. He serves as associate director of the Hematopoietic Stem Cell Transplantation and Cell Therapy program and leads several clinical trials. Dr. Al-Juhaishi trained at Weill Cornell Medicine, VCU, and MD Anderson Cancer Center. Listeners will gain valuable insights into the complexities of managing outpatient CAR T therapy and strategies to enhance patient care.

In this episode of ASTCT Talks, host Dr. Andrés Gómez De León is joined by Dr. Nandita Khera and Dr. Alexandra Gomez Arteaga to explore the critical issue of disparities and barriers to care in graft-versus-host disease (GVHD). The discussion delves into the factors contributing to unequal access to hematopoietic cell transplantation, such as socioeconomic status, race, and ethnicity, both in the U.S. and globally. The guests highlight initiatives like the ACCESS Initiative by ASTCT and the National Marrow Donor Program, aimed at addressing these disparities through advocacy, awareness, and training for junior faculty. They also discuss the importance of caregiver support, clinical trial accessibility, and the broader impacts of GVHD on patients' lives. Tune in to gain valuable insights into ongoing efforts to promote equitable access to life-saving treatments. About Dr. Nandita Khera Nandita Khera is a Professor of Medicine in the Mayo Clinic College of Medicine and a Consultant in the Division of Hematology/ Oncology at Mayo Clinic Arizona. She treats patients with hematological malignancies and some solid tumors, especially those needing blood and marrow transplant/cell therapy (BMT/CT). Her research focuses on improving the delivery of care to patients with cancer including those undergoing BMT/CT to help them be better prepared for the psychosocial and financial consequences of the treatment. She has published several papers in outcomes, late effects, and quality of care in cancer patients and provides mentorship to trainees interested in projects in these areas. She has been a member and has held leadership positions at Mayo Clinic and in the various committees in organizations/ societies in hematology and BMT/CT.. She was the working committee co-chair for the Health Services and International Issues Working committee of CIBMTR from 2015 to 2020 and a member of BMT-CTN SOSS Late Effects committee in 2020. As the co-chair of Dissemination and Implementation committee at BMT CTN currently, she leads efforts in improving translation of evidence into practice in the field of BMT. She is the Director of Community or Clinical Practice at ASTCT. About Dr. Alexandra Gomez Arteaga Dr. Alexandra Gomez Arteaga is an Assistant Professor at Weill Cornell Medicine/NewYork-Presbyterian Hospital and directs the Allogeneic Bone Marrow Transplant Service and the Advanced Fellowship in Bone Marrow Transplantation. She earned her MD from Los Andes University, completed her residency at the University of Miami, her Hematology/Oncology fellowship at Weill Cornell, and her BMT advanced fellowship at Memorial Sloan Kettering Cancer Center. Dr. Gomez's research focuses on improving outcomes in allogeneic stem cell transplantation for leukemia and myeloid malignancies, with an emphasis on young adults and alternative donors. Her work also addresses the critical need to decrease disparities in access to transplantation for minority populations, a cause she champions across her clinical practice, research, and advocacy. She currently serves as the Co-Chair for the Junior Faculty Initiative within the ASTCT ACCESS Initiative. About Dr. Andrés Gómez De León Dr. Andrés Gómez De León (@GomezDLeonMD) is an Associate Professor at Universidad Autonoma de Nuevo Leon in Monterrey Mexico and an ASTCT Content Committee member with an interest in acute leukemias and transplant and cell therapies in low and middle income countries.

In this latest episode of ASTCT Talks, Cory M. Edgar, DMSc, PA-C, sits down with Sarah Fitzmaurice, APRN, where they delve into the evolving landscape of survivorship care, particularly in the realm of CAR T-cell therapy. They discuss the development of CAR T-specific protocols, emphasizing the importance of post-treatment monitoring and patient education. They also explore the challenges of defining survivorship, the multidisciplinary nature of care, and insights into late effects, deconditioning, cognitive changes, and psychological concerns beyond the first year. Tune into this episode of ASTCT Talks for a deep dive into the complexities and triumphs of survivorship care in the post-CAR T-cell therapy era. About Sarah Fitzmaurice, APRN Sarah Fitzmaurice, APRN, is a Nurse Practitioner at the University of Kansas Cancer Center Hematological Malignancies and Cellular Therapeutics. She has practice in transplant and cell therapy for over 10 years, as well as experience with inpatient, outpatient, and apheresis clinical management of patients. For the last 4 years, she has specialized in Cancer Survivorship for patients after stem cell transplant and cellular therapy. She completed her Bachelor of Science in Nursing from Saint Luke's Nursing School and worked as an RN in hematology/oncology for 7 years. She attained her Master's of Science in Nursing as an Adult-Gerontology Nurse Practitioner at KU's School of Nursing in 2013. She holds certifications as an Adult-Gerontology Nurse Practitioner, Blood and Marrow Transplant Certified Nurse, and Tobacco Treatment Specialist. Her interests include late effects and quality of life following stem cell transplant and cellular therapies. About Cory Edgar DMSc, PA-C Cory Edgar DMSc, PA-C, is a physician assistant at the AdventHealth Orlando Blood and Marrow Transplant Center. He established the AdventHealth HCT Survivorship Program and has served as the principal provider of the clinic since 2020. He also holds a joint appointment as an Assistant Professor of Physician Assistant Studies at AdventHealth University. He serves on multiple APP initiatives within ASTCT, including the APP Steering Committee and chairs the APP Research subcommittee. Cory received his undergraduate training at the University of Florida , Master in Physician Assistant Studies from the University of Texas Southwestern (UTSW) Medical Center, and his Doctor of Medical Science from the University of Lynchburg. His research interests include simulation in PA education, hematologic malignancies, cancer survivorship, and APP utilization in oncology specialties.

In this latest episode of ASTCT Talks, the October President's Message, Dr. Andrés Gómez De León is joined by Dr. Miguel Perales, President of ASTCT and Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. They delve into the vital but often overlooked role of physical activity in hematopoietic and cell therapy transplants, discussing challenges, proactive approaches like "pre-hab," the research gap, and the transformative effects of movement on recovery. Click here to listen to this episode in Spanish.

En este último episodio de ASTCT Talks, el Mensaje del Presidente de octubre, el Dr. Andrés Gómez De León está acompañado por el Dr. Miguel Perales, Presidente de ASTCT y Jefe del Servicio de Trasplante de Médula Ósea en Adultos del Memorial Sloan Kettering Cancer Center y Profesor de Medicina en Facultad de Medicina Weill Cornell. Profundizan en el papel vital, pero a menudo pasado por alto, de la actividad física en los trasplantes de terapia celular y hematopoyética, discutiendo desafíos, enfoques proactivos como la "prehabitación", la brecha en la investigación y los efectos transformadores del movimiento en la recuperación.

In this latest episode of ASTCT Talks, Dr. Rebecca Gonzalez sits down with Dr. Katie Gatwood and Dr. Timothy Porter to kick off National Pharmacy Month by discussing the clinical implications of post-transplant cyclophosphamide (PTCy) use outside of the haploidentical setting. They delve into their respective cancer centers' primary donor sources for match unrelated donors and the breakdown of conditioning intensity within their hematologic patients. They delve into the future of PTCy discussing the potential for earlier de-escalation of immunosuppressants to limit drug-related toxicities and optimize patient outcomes as well as important supportive care considerations. Despite the exciting prospects, the need for robust prospective data before implementation is emphasized. About Dr. Rebecca Gonzalez Dr. Rebecca Gonzalez (@xnyerin) received her Doctor of Pharmacy degree from the University of Florida College of Pharmacy. She completed her PGY2 Oncology residency at West Virginia University in Morgantown, West Virginia. Following post-doctoral training, Dr. Gonzalez was a Hematology Clinical Pharmacist at the Roswell Park Cancer Institute prior to transitioning to Moffitt Cancer Center in 2015. She is Board Certified in Oncology Pharmacy and currently practices as a Clinical Pharmacist in Blood and Marrow Transplant/Cellular Immunotherapy at Moffitt in Tampa, Florida. She was a past chair of the ASTCT Pharmacy Program Planning Committee in 2021-2022 and has been involved in several ASTCT teaching activities since 2017. Her interests include survivorship, GVHD, supportive care and infectious disease complications related to transplant and immune cellular therapy. About Dr. Katie Gatwood Dr. Gatwood is a Board-Certified Oncology Pharmacist and Clinical Pharmacist Specialist specializing in Adult Stem Cell Transplant and Cellular Therapy at Vanderbilt University Medical Center. She holds a Doctor of Pharmacy degree from the University of Michigan and completed her residency training at the University of North Carolina Health Care. Dr. Gatwood is the chair-elect of the ASTCT Pharmacy SIG Sterring Committee. She was also awarded the 2021 ASTCT Pharmacy SIG New Practitioner Award and is passionate about clinical research and education, with a focus on VOD, CAR T-cell therapy, and oncology pharmacists' role in ambulatory care. About Dr. Timothy Porter Dr. Timothy Porter is a Board-Certified Oncology Pharmacist and practices as a Clinical Pharmacy Specialist in Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, FL. He earned a Doctor of Pharmacy degree from Duquesne University School of Pharmacy and then completed a PGY1 Pharmacy Residency at Allegheny General Hospital in Pittsburgh, PA, followed by a PGY2 Oncology Pharmacy Residency at The Johns Hopkins Hospital in Baltimore, MD. He then practiced as a Clinical Pharmacy Specialist in Blood and Marrow Transplantation and Cellular Therapy at The Johns Hopkins Hospital before transitioning to Moffitt Cancer Center in 2022. Dr. Porter is a member of the ASTCT Pharmacy SIG Education Committee and serves as the Journal Club Lead. His professional interests include management of infectious complications in immunocompromised patients, GVHD, CAR T-cell therapy, clinical research, and education.

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.      https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score:     https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”.     https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):    https://pubmed.ncbi.nlm.nih.gov/36906275/ 5. ASTCT consensus grading for CRS and ICANS:    https://pubmed.ncbi.nlm.nih.gov/30592986/6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:    https://pubmed.ncbi.nlm.nih.gov/35696759/ 7. Modified EASIX score for predicting CRS and neurotoxicity:    https://pubmed.ncbi.nlm.nih.gov/34432870/

In this latest episode of ASTCT Talks, the June President's Message, we are joined by Dr. Miguel Perales, President of ASTCT and Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College. This episode features a personal story of a patient with aggressive lymphoma who initially had doubts about the effectiveness of transplantation but ultimately experienced a fulfilling life post-transplant. Dr. Perales' story underscores the significance of educating colleagues about improved outcomes and advancements in cell therapies. He also delves into the primary barriers to access in the field and the initiatives undertaken by ASTCT to address these obstacles, aiming to ensure patients receive life-saving treatments. Listeners can gain insights into the actions that the ASTCT community can take to combat misconceptions, including engaging with local physicians, providing educational resources, and fostering collaboration between academic centers and community practitioners.

In this latest episode of ASTCT Talks, Dr. Genovefa Papanicolaou, MD sits down with Dr. Richard J. O'Reilly, MD and Professor Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath to discuss Virus-Specific T-Cells (VST). They dive into what VSTs are, safety of VSTs, challenges and opportunities of adoptive cell therapy for viruses and more. Disclaimer: Dr. Richard O'Reilly received royalties following licensure of the EBV-specific T-cell bank by Atara Biotherapeutics and has subsequently received research support and consultant fees from Atara Biotherapeutics. About Genovefa Papanicolaou, MD Genovefa Papanicolaou (@GenPapaMD) is an infectious disease physician at Memorial Sloan Kettering Cancer Center and professor at Weill Cornell Medical College of Cornell University in New York. She is the past Chair of the Transplant Infectious Disease Special Interest Group (TID-SIG) of ASTCT (2021-2023). Her research areas of interest include viral infections, biomarkers, and personalized infection management. About Richard J. O'Reilly, MD Richard J. O'Reilly, MD is the Claire L. Tow Chair in Pediatric Oncology Research and former Chair of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center. As Chief of the Bone Marrow Transplantation Services in both the Departments of Pediatrics and Medicine, Dr. O'Reilly pioneered transplantation approaches for patients who lack HLA matched siblings. He and his colleagues introduced the use of marrow transplants from matched unrelated donors and thereafter T-cell depleted transplants from HLA half matched donors for children with lethal immune deficiencies and both children and adults with leukemia.  In 1994, he introduced the use of transplant donor T-cells for the treatment of EBV-induced lymphomas. Currently, he is evaluating  adoptive cell therapy employing banked partially HLA-matched and appropriately HLA restricted T-cells from third party healthy donors for viral infections and  leukemias, conducting Phase I and II trials testing adoptive transfer of these  virus-specific and tumor-specific T-cells following T-cell depleted HCT as a therapeutic approach for EBV lymphoproliferative disease, drug resistant CMV infections and leukemic relapse in the post transplant period.  About Professor Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath Karl completed his medical training at Cambridge and Oxford Universities. Following specialisation in Haematology, he spent 5 years developing adoptive cellular therapies for viruses at UCL. After taking the position Head of Adult Stem Cell Transplantation Services at UCLH, he spent 3 years at Memorial Sloane Kettering Cancer Center, NY in the laboratory of Dr James Allison, contributing to the body of work underpinning checkpoint blockade that led to the Nobel Prize for Medicine in 2018. On his return, he continued his work in the field of anti-viral T cell therapies, established the clinical translational side of the academic CAR T cell programme at UCLH and ran a joint Research Laboratory with Professor Sergio Quezada in the UCL Cancer Institute from 2010-2021, becoming Head of the Academic Research Department of Haematology in 2019 and Director of the Sir Naim Dangoor Centre for Cellular Therapy. He was a co-founder of Achilles Therapeutics in 2016, transitioning to the CMO role in 2021.

In this latest episode of ASTCT Talks, Dr. Steven Pergam talks with Dr. Amy Spallone and Dr. Emily Ford to discuss Monkeypox in HCT and CAR T. They cover the basics of Monkeypox, risk factors for Monkeypox among patients, presenting symptoms for Monkeypox, vaccines for Monkeypox and more. About Dr. Steven Pergam Dr. Steven Pergam (@PergamIC) is an Infectious Diseases Physician and Professor at the Fred Hutchinson Cancer Center in the Division of Vaccine and Infectious Diseases. He is also the Infection Prevention Director of the Cancer Center, and a faculty member of the University of Washington's Division of Allergy & Infectious Diseases. His research focuses on the epidemiology, treatment and prevention in high-risk immunosuppressed cancer patients. He is particularly interested in vaccines and hospital acquired pathogens, and is a member of the ASTCT Infectious Diseases Special Interest Group. About Dr. Amy Spallone Dr. Amy Spallone (@A_Spallonii) is an Infectious Diseases physician at the University of Texas MD Anderson Cancer Center. After completing a 2-year clinical fellowship and a 1-year advanced research fellowship at Baylor College of Medicine, she joined the faculty in 2021 at MD Anderson, where she is the Associate Chief Infection Control Officer and Patient Safety & Quality Officer in her department. She is also involved in numerous treatment and lab-based clinical trials focused on viral pathogens in patients with hematologic malignancies and recipients of hematopoietic cell transplants and cellular therapies About Dr. Emily Ford Dr. Emily Ford is an Assistant Professor at the University of Washington and an Associate in the Vaccine and Infectious Diseases Division at the Fred Hutchinson Cancer Center. She is a physician on the Infectious Diseases consult service at the Fred Hutchinson Cancer Center and in the Roosevelt Virology Clinic at the University of Washington in Seattle.

In the next installment of ASTCT's Titans of Transplant series, Dr. John. F. DiPersio, an internationally recognized leader in hematopoietic stem cell transplantation and acute leukemia and past president of ASTCT (2019) is interviewed by Dr. Roman Shapiro. About Dr. John F. DiPersio John F. DiPersio, MD, PhD is deputy director at Alvin J. Siteman Cancer Center, director at Center for Gene and Cellular Immunotherapy and chief of the division of oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman professor of medicine. His research focuses on mechanistic and translational aspects of leukemia and stem cell biology. He has played a key role in the clinical development of plerixafor as a mobilizing agent for stem cell transplantation. DiPersio has played a key leadership role in the team-science work at Washington University that has defined the genetic and epigenetic factors that contribute to clonal evolution and relapse in AML. He has served in leadership roles for the American Society of Hematology (ASH), multiple NIH, CIRM, LLS, and CPRIT Study Sections, and has served on NCI's Board of Scientific Counselors. He is an elected member of ASCI and AAP, and past president of the American Society of Transplantation and Cellular Therapy (2019). About Dr. Roman Shapiro Roman Shapiro, MD is a physician working with the bone marrow transplantation group at the Dana-Farber Cancer Institute. His main clinical and academic interest is the prevention and treatment of malignant disease following stem cell transplant. His contributions to science include optimizing the use of natural killer (NK) cell therapy, including cytokine-induced memory-like (CIML) NK cells, for the prevention and treatment of post-transplant relapse of myeloid disease. The Titans of Transplant series seeks to recognize, celebrate and chronicle the physicians, researchers, pharmacists, nurses, social workers and more who were on the frontlines of the early days of transplant.

ASTCT Talks: Celebrating Advocacy Efforts, Overcoming Barriers and Addressing Inequity in Cellular Transplantation In this latest episode of ASTCT Talks, we celebrate National Hispanic Heritage Month as Dr. Jennifer Saultz talks with Dr. Eneida Nemecek to highlight her work and share her advocacy, passion and journey to becoming a medical director of clinical research. She explains her experiences as a Latina woman in the field of cellular therapy and transplantation, barriers Hispanic and marginalized groups face in cellular transplantation, inclusivity efforts for health equity, the value of mentor and sponsorship and more. About Dr. Jennifer Saultz Dr. Jennifer Saultz is an Assistant Professor of Medicine at Oregon Healthy & Science University and a member of the Adult Transplant and cellular therapy team. Her research focuses on the innate immune resistance signatures in AML. She is also a member of the ASTCT Content Committee. About Dr. Eneida Nemecek Dr. Eneida Nemecek is a Professor of Pediatrics and Medical Oncology and Medical director of Clinical Research at the Knight Cancer Institute-Oregon Health & Science University (OHSU) in Portland, Oregon. Her research focuses on bone marrow and cellular therapies, and health services research addressing disparities in access for underrepresented groups. She has served in leadership roles in steering committees for several NIH/NCI-funded cooperative groups. She has also held elected leadership positions as director, trustee or committee chair in multiple organizations including Be The Match/National Marrow Donor Program, Blood and Marrow Transplant Clinical Trials Network, the Pediatric Blood and Marrow Transplant Consortium, American Society of Transplant and Cellular Therapies, American Society of Hematology and Foundation for the Accreditation of Cellular Therapy.

In this latest episode of ASTCT Talks, Dr. Andrés Gómez De León, a physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Dr. Cristóbal Frutos, who is the Coordinator for the Bone Marrow transplant Unito the Hospital Central Instituto de Previsión Social in Asunción Paraguay, discuss the current state of transplant activities and the importance of having access to cell therapies worldwide. Dr. Frutos presented on this topic during the 2022 Tandem Meetings of ASTCT & CIBMTR.

During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings), the GvHD Hub was pleased to speak to Gérard Socié, Hôpital Saint-Louis, Paris, FR. We asked, How would you treat acute GvHD (aGvHD) in your clinic (an EU perspective)?Socié begins by highlighting the main differences between aGvHD treatment in the EU and in the US. Socié then discusses the use of steroids in aGvHD treatment, despite 40–50% of patients becoming steroid-resistant. Finally, Socié talks about the current standard of care in steroid-resistant aGvHD. Hosted on Acast. See acast.com/privacy for more information.

Guest host, Dr. John Sweetenham, associate director for Clinical Affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and Dr. Syed Abutalib, medical director of the Hematologic Malignancies and Stem Cell Transplant Program at the Cancer Treatment Centers of America in Zion, Illinois, discuss advances in CAR T-cell therapy in the management of lymphoma, the toxicities associated with CAR T, and emerging bispecific antibodies for the treatment of lymphomas.   Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News podcast. I'm John Sweetenham, the associate director for Clinical Affairs at UT Southwestern Harold C. Simmons Comprehensive Cancer Center and guest host of the podcast. I'm delighted to welcome my friend, Dr. Syed Abutalib, the medical director of the Hematologic Malignancies and Stem Cell Transplant Program at the Cancer Treatment Centers of America in Zion, Illinois. He's also associate professor at the Rosalind Franklin University of Medicine and Science, and founder and co-editor of Advances in Cell and Gene Therapy. Today, we're going to be discussing some of the recent advances in the use of CAR T-cell therapy in the management of lymphoma. Our full disclosures are available in the show notes, and disclosures relating to all episodes of the podcast can be found in our transcripts at asco.org/podcasts. Syed, it's great to have you on the podcast today. Thanks for coming. Dr. Syed Abutalib: Thank you, John. It's my honor. Dr. Sweetenham: Syed, the emergence of CAR T-cell therapy is having a transformed impact on the treatment landscape for hematologic malignancies in general, and for lymphoma in particular, and I'd like to give our listeners a sense of where we're at with CAR T-cell lymphoma. Can you tell us a little about the FDA approved agents which are now being used for the management of patients with malignant lymphoma? Dr. Syed Abutalib:  Sure, so there are, at this time, about five agents that are approved based on mainly a phase 2 single arm study controlling them with the historical data from Scholar One in diffuse large B-cell lymphoma. They are axicabtagene ciloleucel. We'll be calling this axi-cel, which was approved after the data ZUMA-1 for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. In this group, there were diffuse large B-cell lymphoma NOS, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and transformed diffuse large B-cell lymphoma from follicular lymphoma. The next agent that was approved was--let's see if I can pronounce it. It's the most difficult name--tisagenlecleucel which is tisa-cel was based on the JULIET trial. This drug was approved again for the adult patients with a relapsed/refractory large B-cell lymphoma after two lines of systemic therapy for the same indications as patients in ZUMA-1 trial except tisa-cel is not approved for the primary mediastinal large B-cell lymphoma. The next agent is lisocabtagene maraleucel. We will call this liso-cel. This agent was approved after the pivotal trial TRANSCEND NHL 001. And the unique thing about this trial was also there were two patients with CNS lymphoma in this trial. And again, the indications were similar to the axi-cel indication. And the fourth indication is for axicaptagene lisoleucel based on the ZUMA-5 trial, which was FDA approved for adult patients with relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. And the last agent that has been approved is based on the trial of ZUMA-2, which is brexucabtagene autoleucel, brexu-cel. And this is approved for adult patients with relapsed or refractory mantle cell lymphoma. Dr. John Sweetenham: Syed, thanks for providing that background. As you've shown, there are multiple agents which have been through early phase clinical trials. They've been applied to various subtypes of malignant lymphoma. And furthermore, they've been used at various stages in the treatment algorithm for these lymphomas, albeit mostly in the relapsed and refractory setting. We've all been waiting for some time to start to see data emerging from prospective randomized trials of CAR T-cell therapy versus standard of care. And of course, we were exposed to some of the early data from these randomized trials at the American Society of Hematology Annual Meeting in December. And overall, there was the suggestion of a possible benefit to CAR T-cell therapy. Could you tell us a little bit about the data that caught your attention and your insights into how to interpret those data? Dr. Syed Abutalib: Yeah, definitely. So as I alluded earlier, right now, the FDA approval is mainly for patients after two lines of therapy in diffuse large B-cell lymphoma. Now what is happening is that this CAR T-cell is trying to move forward into failure after first line of therapy. And in order to do that it is important that they have a comparative arm, which they tried to do in three trials by comparing it with so-called standard of care therapy. However, it must be noted that the standard of care therapy in diffuse large B-cell is not that straightforward for all patients who relapse. So just to give you the background, about 30% to 40% of the patients with diffuse large B-cell lymphoma experience relapse, and 10% are refractory to first line therapy. Now out of these patients, the standard of care therapy applies in real world practice as to the patients who are transplant eligible. For the remaining patients who are transplant ineligible, there is no standard of care therapy. And the list is very long if you look at the NCCN guidelines for those patients. And the patients who are transplant eligible; if 100 patients go to transplant, 50% are cured. And there is a very good track record for this. And the ones who are cured are mainly the ones who are sensitive to chemotherapy, mainly platinum-based chemotherapy. So what these trials that were presented at ASH, one has to understand that what they call standard of care in their comparative arm because what happens is that if you have a comparative arm that is weak, that is not transplant-eligible patients, or the patients don't go to transplant, then your trial would look much better than what it really is. So there were three trials that caught my attention. One is, of course, ZUMA-7, the axi-cel and the second one is the TRANSFORM trial with liso-cel. And the third one is the BELINDA trial, tisa-cel.  ZUMA-7 and BELINDA trial have been published in the New England Journal of Medicine already. So what is important to acknowledge here is that the patients in ZUMA-7 were refractory to frontline therapy. About 74% of those patients were refractory, meaning that they did not respond to [INAUDIBLE]. Now we don't know how bad the refractory disease was, and ideally, these patients, if they are transplant eligible, which most of the patients were, would have gone to auto transplant, and 50% of them historically would be cured and the other patients who are relapsed within 12 months to frontline therapy. Now in ZUMA-7, they assumed that these patients who are early relapse will not respond to standard of care transplant. They divided those patients to CAR-T versus transplant or non-transplant. The reason I say non-transplant, because only 36% of the patients who were on ZUMA-7 received what you call, ‘standard of care therapy,' high dose chemotherapy with transplant. So I don't think it was a fair comparison to standard of care therapy. Now the other thing is the follow up is not too long as it is for the auto transplant. So it remains to be seen how things will evolve. In the TRANSFORM trial, which was with the liso-cel, the large cell lymphoma group were either primary refractory or relapsed within 12 months. Again, they assume that the patients who relapsed early will not respond to platinum-based therapy. Ideally, these patients should go for auto-transplant. In BELINDA trial, what is significant is that only 23% of the patients received auto transplant. And out of the three transplants, BELINDA trial was the only one which did not show improvement in median event-free survival compared to the standard of care. The hazard ratio was 1.01. So it's difficult to say that these trials are truly positive for CAR-T over auto transplant because they did not compare auto transplant in the CAR-T. They compared all patients with relapsed or refractory disease who could have gotten transplant also to CAR-T, favoring the experimental arm. Dr. John Sweetenham: Yeah, thanks Syed. So I think the take-home message that I'm hearing from you is that there are some interesting signals in these randomized studies about the potential efficacy of CAR-T. It's probably a little bit early to claim victory just yet, and we need to let these studies mature out a bit more and I guess ultimately wait for some overall survival endpoints. You're absolutely right that there is still some uncertainty surrounding the interpretation of these results and the long-term effectiveness of CAR T-cell therapy. One thing there's no doubt about is that CAR T-cell therapy is associated with significant toxicities, the most common being Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome, or ICANS. But of course, the list of adverse events is much longer. We recognize late toxicities, including prolonged cytopenias. So right now, CAR T-cell therapy is mainly performed at larger tertiary care centers, but obviously, things are changing as regional facilities begin to do CAR T-cell therapies themselves. And even if they don't actually provide CAR T-cell therapy, a lot of physicians are going to be seeing their patients locally after they have developed toxicities from this treatment. How far have we come, do you think, in managing the toxicities of CAR-T, and how can we better manage those adverse events in our patients as we move forward and it becomes a more widespread intervention? Dr. Syed Abutalib: I believe we are getting better in managing these therapies, but of course, the CAR T-cell therapy is at its infancy, and we are learning. In any case, it is important to understand what are the main toxicities-- as you had mentioned, the CRS and the neurotoxicity and the chronic B-cell achalasia or hypogammaglobulinemia, which basically reflects the persistence of CAR T-cell therapy. So, in an effort to improve on recognition and treatment of these side effects, ASTCT, which is the American Society of Transplant and Cellular Therapy, had the workshop in 2018 in Washington DC, and they published a paper subsequently in trying to educate everybody about these toxicities. What is important in CRS is early recognition, and CRS is divided into different grades according to the ASTCT criteria from grade 1 to grade 4. Grade 1 is when you have fever. Many patients that we will admit or who we will treat who are very sick patients will get fever. One should not assume that it is CRS. We should always exclude the infection and start the appropriate antibiotics. And as a transplanter, we are very well-aware of how to tackle this or as treating hematologic malignancies with a lot of neutropenic fevers. So, if you have fever, appropriate workup should be done. Grade 2 ASTCT criteria is fever with hypotension that does not require pressors or hypoxia that requires low-flow nasal-cannula oxygen. Grade 3 is worsening of the hypotension, requiring pressors without vasopressin or hypoxia getting worse. And grade 4 is an extreme with multiple pressures requirement for hypertension and hypoxia requiring CPAP or BiPAP. So all this requires close monitoring and one should also recognize the risk factors prior to the admission of the patient or prior to giving the CAR-T. What are the risk factors for this CRS. The risk factors, which include our high pre-infusion tumor burden, so it is important sometimes to debulk the patient.  Early onset of fever, presence of underlying inflammatory process or presence of infection--these things will help manage the CRS. The other thing is the neurotoxicity. And similarly, there has been criteria developed for that too.  There's an algorithm at our institution, we have developed a card that has this criteria and algorithm imprinted on it. So, there is an ICE criteria which basically checks for patient orientation. And you have certain questions about ability to name three objects, following commands, writing, and attention. You give them certain points. And then you have them go into the neurotoxicity domain and check the level of consciousness and/or their seizures or motor findings or elevated cerebral intracranial pressures. So based on that, you find out what is their neurotoxicity grade. Having said that, it is also important to have toci, which is IL-6 inhibitor, on hand. And according to the regulatory authorities, these drugs are approved under the REMS program. So you have to have at least two doses of tocilizumab in-house before you give any patient these drugs. So, to answer your question in a nutshell now is that close hemodynamic monitoring is very important, and it is important to have trained staff on board who can check on patients at regular, frequent intervals to recognize these toxicities early and intervene early to prevent morbidity and mortality. Dr. John Sweetenham: Yes, thanks. And I think it emphasizes the fact that the initial patient selection for CAR T-cell therapy is extremely important bearing in mind not just the patient's disease state but also age, performance status, co-morbidities, and so on in the same way, really, as with transplant. I want to change gears just for a moment. There is no doubt that cellular immunotherapies like CAR-T remain of limited availability in part because of cost and effectiveness barriers. And without getting into a long discussion about that, I wonder if you could comment a little bit on other emerging therapies that in time could potentially, if it's the right expression, challenge CAR T-cell. I'm thinking in particular about some of the bispecific T-cell engaging antibodies which are now coming online. Dr. Syed Abutalib: Sure. So the bispecific antibodies are basically protein constructs with a specificity to two different antigens. And they commonly bind immune effector cell antigens and tumor-specific antigens, creating what we call an immune synapse, which results in activation of the effector cells, which are T-cells, and cause direct cytotoxic activity. For example, we have an FDA-approved agent in ELL, and it's also listed in NCCN as an-- in transplant-ineligible patients, which is blinatumomab, which is a CD3 and CD19 construct. Now in the clinical trials, there are many bispecific antibodies that are in development. The benefit of this is manifold, in my opinion. They are off-the-shelf immunotherapy. They have strategies to mitigate CRS and neurotoxicities such as that they are given those adjustments with lower rates of doses early on and then the dose is escalated. And we see less CRS and neurotoxicity in patients. The third advantage is they might be preferable, especially in older adults.  I'm not sure if they are going to replace the auto transplant at this time. The other advantage is that there is data emerging that they are effective even after CAR T-cell therapy failures although the data is not mature yet. And still, we need them to be approved and see how they will be in the real world setting. So some of them I will talk about. The one that really caught my attention was mosunetuzumab, which is called mosun. The unique thing about this is that it's IV, and there is a step up dosing to mitigate the CRS and neurotoxicity as I mentioned.  And it is a time limited therapy. It's not that you have to keep going, and that is important because of the cost effectiveness of the therapy. And this is a CD3 and CD20 construct. It is being tested in the third line follicular lymphoma as monotherapy in combination of Revlimid. The important thing is that the CR grade 3 and grade 4, very few patients, 2 patients out of 90 in follicular lymphoma, and no grade 4, grade 5 events occurred whether with monotherapy in follicular lymphoma with a CR rate of about 58%. They are also being combined with polatuzumab, which is an anti-CD79 antibody and also in relapsed/refractory diffuse large B-cell lymphoma as a subcutaneous dose because of, again, further trying to mitigate the CRS with a slow release form. The other important biphasic antibody is glofitamab, which is being tested in relapsed/refractory follicular lymphoma, relapsed/refractory mantle cell lymphoma after BTKI, failures. And also, the data in more than 200 patients was presented in patients with diffuse large B-cell lymphoma, mantle cell lymphoma, transformed follicular lymphoma, Richter syndrome. So these two are very important to watch for. There are others, such as epcoritamab, which is also C3 and CD20 bispecific antibody, which is also in a phase III trial, what is the standard of care in relapsed/refractory diffuse large B-cell lymphoma, and is also being tested upfront with R-CHOP. So I think these three are important to watch out for, and in my opinion, which might be incorrect, these are, as I alluded earlier, are more convenient, less laborious, can be less CRS, and might have about similar-- might have similar activity as CAR-T, might win the game over CAR-T. But it's too early to say. It's just an opinion. Dr. John Sweetenham:  Thanks, Syed. And I think however this plays out, however, ultimately, these bispecific antibodies line up versus CAR T-cell therapy, I think two things are true for sure. The first of those is that patients with aggressive lymphomas and indolent lymphomas now have available to them a number of treatment options they didn't have before, which, of course, is great news. The second thing which is undoubtedly true is at least for a while, CAR-T therapy is with us to stay. Syed, it's been a pleasure having you on the podcast today and hearing your insights into how CAR T-cell therapy is evolving and its potential to improve patient outcomes in the future. Dr. Syed Abutalib: Thank you, John. Dr. John Sweetenham: And thank you to our listeners for your time today. If you enjoyed this episode, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness   Dr. Syed Abutalib: None Disclosed   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

This episode of ASTCT Talks features a recently recorded conversation with Dr. John DiPersio, a Bone Marrow Transplant Specialist and Medical Oncologist at the Siteman Cancer Center at the Washington University School of Medicine, and a past president of ASTCT. We discuss emerging therapies to treat AML, advancements in immunotherapies, and much more.

This episode discusses CMV cell mediated immunity and the recently released white paper evaluating various methodologies, including Viracor's CMV T Cell Immunity Panel. Episode Links: Eurofins Viracor CMV information Eurofins Viracor CMV T Cell Immunity Panel View our product theater presented during TCT 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR "Post-Transplant Prevention and Management of Cytomegalovirus" Social Media: Linkedin   |   Twitter   |   Facebook For more information visit: Eurofins-Viracor.com or call (800)305-5198  

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/JHF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView CME-certified activity, which is based on a live symposium held adjunct to the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, features expert guidance on the rapidly changing clinical landscape in multiple myeloma (MM), grounding the recent changes in myeloma care squarely within the context of current recommendations for transplant-eligible patients. Each scientific session explores new data with next-generation proteasome inhibitors and immunomodulatory agents, established and emerging antibodies, cell-based therapy, and newer intracellularly targeted options for ASCT-eligible populations, and includes clinical “take homes” designed to capture the major implications of the evidence presented. Upon completion of this activity, participants should be better able to: Cite current practice recommendations for transplant eligibility, minimal residual disease monitoring, and the role of novel therapeutic platforms in the setting of multiple myeloma, Discuss evidence related to the efficacy and safety of novel therapeutic platforms based on next-generation proteasome inhibitors, immunomodulatory drugs, novel antibodies, and new therapeutic drug classes in conjunction with autologous stem cell transplantation (ASCT) in the management of patients with multiple myeloma, Recommend optimized induction and post-ASCT maintenance/consolidation regimens for eligible patients with multiple myeloma, Develop novel therapeutic platforms for the management of relapsed multiple myeloma post-ASCT, including in the setting of early relapse or treatment-refractory disease.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.

Go online to PeerView.com/DYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In PeerView's latest CME-certified onDemand activity, based on a symposium at the 2020 Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, experts lead a series of evidence-based “MasterClass” scientific discussions exploring the nuances of VOD risk assessment, diagnosis, and treatment. The experts also share their perspectives on several adult and pediatric patient cases designed to illustrate how clinicians can “follow the evidence” to apply new recommendations for VOD management and overcome the challenges associated with this serious post-transplant complication. Upon completion of this activity, should be better able to: Identify updated risk factors for VOD, modern diagnostic criteria, and clinical markers of disease severity, Confirm a diagnosis of VOD/SOS in adult and pediatric patients, including those presenting with or without organ dysfunction, in the post-HCT setting, Select optimal treatment for patients with VOD/SOS post-HCT, including those patients exhibiting multi-organ dysfunction or rapidly progressive disease, Cite the role of established and emerging therapeutics as pharmacologic prophylaxis for VOD/SOS.